{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:31:10Z","timestamp":1792755070538,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01461-7","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T11:43:26Z","timestamp":1773143006000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Toward a cure for multiple myeloma within a decade"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3474-0002","authenticated-orcid":false,"given":"Florent","family":"Malard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Facon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Harousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"1461_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","volume":"10","author":"F Malard","year":"2024","unstructured":"Malard F, Neri P, Bahlis NJ, Terpos E, Moukalled N, Hungria VTM, et al. Multiple myeloma. Nat Rev Dis Prim. 2024;10:45.","journal-title":"Nat Rev Dis Prim"},{"key":"1461_CR2","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1182\/blood.2021012854","volume":"138","author":"M Mohty","year":"2021","unstructured":"Mohty M, Avet-Loiseau H, Harousseau J-L. Requirements for operational cure in multiple myeloma. Blood. 2021;138:1406\u201311.","journal-title":"Blood"},{"key":"1461_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01312-x","volume":"15","author":"I Ntanasis-Stathopoulos","year":"2025","unstructured":"Ntanasis-Stathopoulos I, Filippatos C, Malandrakis P, Kastritis E, Terpos E, Dimopoulos M-A, et al. Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies. Blood Cancer J. 2025;15:104.","journal-title":"Blood Cancer J"},{"key":"1461_CR4","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1056\/NEJMoa2409029","volume":"392","author":"MA Dimopoulos","year":"2025","unstructured":"Dimopoulos MA, Voorhees PM, Schjesvold F, Cohen YC, Hungria V, Sandhu I, et al. Daratumumab or active monitoring for high-risk smoldering multiple myeloma. N Engl J Med. 2025;392:1777\u201388.","journal-title":"N Engl J Med"},{"key":"1461_CR5","first-page":"4056","volume":"109","author":"N Puig","year":"2024","unstructured":"Puig N, Agull\u00f3 C, Contreras T, P\u00e9rez JJ, Aires I, Calasanz MJ, et al. Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial. Haematologica. 2024;109:4056\u201366.","journal-title":"Haematologica"},{"key":"1461_CR6","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1182\/blood-2022-168930","volume":"140","author":"SK Kumar","year":"2022","unstructured":"Kumar SK, Alsina M, Laplant B, Badros AZ, Abdallah A-O, Abonour R, et al. Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial. Blood. 2022;140:1830\u20132.","journal-title":"Blood"},{"key":"1461_CR7","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1182\/blood-2023-177954","volume":"142","author":"O Nadeem","year":"2023","unstructured":"Nadeem O, Magidson S, Midha S, O\u2019Donnell EK, Hartley-Brown MA, Sperling AS, et al. Immuno-PRISM: a randomized phase II platform study of bispecific antibodies in high-risk smoldering myeloma. Blood. 2023;142:206.","journal-title":"Blood"},{"key":"1461_CR8","first-page":"2420","volume":"109","author":"M Engelhardt","year":"2024","unstructured":"Engelhardt M, Kort\u00fcm KM, Goldschmidt H, Merz M. Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible. Haematologica. 2024;109:2420\u201335.","journal-title":"Haematologica"},{"key":"1461_CR9","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1200\/JCO.23.01277","volume":"42","author":"F Maura","year":"2024","unstructured":"Maura F, Rajanna AR, Ziccheddu B, Poos AM, Derkach A, Maclachlan K, et al. Genomic classification and individualized prognosis in multiple myeloma. J Clin Oncol: Off J Am Soc Clin Oncol. 2024;42:1229\u201340.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"1461_CR10","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1182\/blood.2023020284","volume":"142","author":"M Mohty","year":"2023","unstructured":"Mohty M, Avet-Loiseau H, Malard F, Harousseau JL. Potential future direction of measurable residual disease evaluation in multiple myeloma. Blood. 2023;142:1509\u201317.","journal-title":"Blood"},{"key":"1461_CR11","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/blood.2020010439","volume":"139","author":"J San-Miguel","year":"2022","unstructured":"San-Miguel J, Avet-Loiseau H, Paiva B, Kumar S, Dimopoulos MA, Facon T, et al. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood. 2022;139:492\u2013501.","journal-title":"Blood"},{"key":"1461_CR12","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1182\/bloodadvances.2024014097","volume":"9","author":"LY Chen","year":"2025","unstructured":"Chen LY, Thibaud S, Bodnar S, Chari A, Richter J, Cho HJ, et al. MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myeloma. Blood Adv. 2025;9:176\u20139.","journal-title":"Blood Adv"},{"key":"1461_CR13","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024;390:301\u201313.","journal-title":"N Engl J Med"},{"key":"1461_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01156-x","volume":"14","author":"BA Derman","year":"2024","unstructured":"Derman BA, Major A, Cooperrider J, Jiang K, Ramsland A, Karrison T, et al. Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 2024;14:170.","journal-title":"Blood Cancer J"},{"key":"1461_CR15","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1093\/annonc\/mdx340","volume":"28","author":"H Takamatsu","year":"2017","unstructured":"Takamatsu H, Takezako N, Zheng J, Moorhead M, Carlton VEH, Kong KA, et al. Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation. Ann Oncol. 2017;28:2503\u201310.","journal-title":"Ann Oncol"},{"key":"1461_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00794-x","volume":"13","author":"R Fonseca","year":"2023","unstructured":"Fonseca R, Arribas M, Wiedmeier-Nutor JE, Kusne YN, Gonz\u00e1lez V\u00e9lez M, Kosiorek HE, et al. Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients. Blood Cancer J. 2023;13:32.","journal-title":"Blood Cancer J"},{"key":"1461_CR17","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1200\/JCO.22.01916","volume":"41","author":"L Burgos","year":"2023","unstructured":"Burgos L, Tamariz-Amador LE, Puig N, Cedena MT, Guerrero C, Jel\u00ednek T, et al. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies. J Clin Oncol : Off J Am Soc Clin Oncol. 2023;41:3019\u201331.","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"key":"1461_CR18","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1038\/leu.2013.166","volume":"27","author":"B Paiva","year":"2013","unstructured":"Paiva B, V\u00eddriales MB, Rosi\u00f1ol L, Mart\u00ednez-L\u00f3pez J, Mateos MV, Ocio EM, et al. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control. Leukemia. 2013;27:2056\u201361.","journal-title":"Leukemia"},{"key":"1461_CR19","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1056\/NEJMoa2505133","volume":"393","author":"A Perrot","year":"2025","unstructured":"Perrot A, Lambert J, Hulin C, Pieragostini A, Karlin L, Arnulf B, et al. Measurable residual disease-guided therapy in newly diagnosed myeloma. N Engl J Med. 2025;393:425\u201337.","journal-title":"N Engl J Med"},{"key":"1461_CR20","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","volume":"391","author":"T Facon","year":"2024","unstructured":"Facon T, Dimopoulos MA, Leleu XP, Beksac M, Pour L, H\u00e1jek R, et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391:1597\u2013609.","journal-title":"N Engl J Med"},{"key":"1461_CR21","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","volume":"30","author":"X Leleu","year":"2024","unstructured":"Leleu X, Hulin C, Lambert J, Bobin A, Perrot A, Karlin L, et al. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. Nat Med. 2024;30:2235\u201341.","journal-title":"Nat Med"},{"key":"1461_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01115-6","volume":"14","author":"M Mohty","year":"2024","unstructured":"Mohty M, Facon T, Malard F, Harousseau J-L. A roadmap towards improving outcomes in multiple myeloma. Blood Cancer J. 2024;14:135.","journal-title":"Blood Cancer J"},{"key":"1461_CR23","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1200\/JCO-25-00760","volume":"43","author":"S Jagannath","year":"2025","unstructured":"Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, et al. Long-Term (\u22655-Year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma. J Clin Oncol : Off J Am Soc Clin Oncol. 2025;43:2766\u201371.","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"key":"1461_CR24","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/leu.2012.160","volume":"27","author":"SZ Usmani","year":"2013","unstructured":"Usmani SZ, Crowley J, Hoering A, Mitchell A, Waheed S, Nair B, et al. Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured? Leukemia. 2013;27:226\u201332.","journal-title":"Leukemia"},{"key":"1461_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0155-7","volume":"8","author":"SZ Usmani","year":"2018","unstructured":"Usmani SZ, Hoering A, Cavo M, Miguel JS, Goldschimdt H, Hajek R, et al. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project. Blood Cancer J. 2018;8:123.","journal-title":"Blood Cancer J"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01461-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01461-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01461-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T08:34:01Z","timestamp":1773909241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01461-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1461"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01461-7","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"17 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MM reports grants and lecture honoraria from Janssen, Sanofi, Maat Pharma and JAZZ Pharmaceuticals, lecture honoraria from Celgene, Amgen, BMS, Takeda, and Pfizer, grants from Roche, all outside the submitted work. FM reports lecture honoraria from Sanofi, Novartis, BMS, Astrazeneca, Therakos, Priothera, MSD and Jazz Pharmaceutical all outside the submitted work. The other authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}